tau PET、淀粉样蛋白PET与海马体积对阿尔茨海默病认知的影响
研究纳入152名具有至少2次临床和认知评估、临床痴呆评定量表评分为0或0.5、并接受flortaucipir tau PET、florbetapir淀粉样蛋白PET及结构MRI扫描的中老年参与者,探讨神经影像生物标志物对回顾性认知下降的独立和交互影响。结果显示,单变量分析中每个标志物均与全局认知复合评分相关,但多变量模型中仅tau是全局认知下降的显著预测因子;tau与淀粉样蛋白存在交互作用,高淀粉样蛋白个体中tau相关认知下降更严重;三种病理均高的个体认知下降最大。
要点
- 多变量模型中仅tau是全局认知下降的显著预测因子。
- tau与淀粉样蛋白存在交互作用,高淀粉样蛋白个体中tau相关认知下降更严重。
- tau对情景记忆和执行功能测验的负面影响最大。
核心结论
- 结果提示tau水平升高与生物标志物采集前的认知下降最一致相关。
- 这些发现支持阿尔茨海默病分期模型,即单纯β-淀粉样蛋白升高可能不足以在阿尔茨海默病风险个体中产生认知变化,并支持使用多种生物标志物进行阿尔茨海默病进展分期。
研究设计与样本
- 从圣路易斯华盛顿大学Knight阿尔茨海默病研究中心招募152名中老年参与者,均具有至少2次临床和认知评估、临床痴呆评定量表评分为0或0.5、flortaucipir(18F-AV-1451)tau PET扫描、florbetapir(18F-AV-45)淀粉样蛋白PET扫描和结构MRI扫描。
- 采用反映情景记忆、执行功能、语义流畅性和处理速度的标准量表评估认知。
主要发现
- 回顾性纵向分析显示,每个生物标志物在单变量分析中均与全局认知复合评分相关;但在单一统计模型中分析每个标志物时,仅tau是全局认知下降的显著预测因子。
- tau与淀粉样蛋白存在交互作用,高淀粉样蛋白个体中tau相关认知下降更严重。
- tau与海马体积存在交互作用,表明三种病理均高的个体认知下降最大。
- 在各认知域内分析表明,tau对情景记忆和执行功能测验的负面影响最大。
临床怎么用
- 作者认为,这些发现支持使用多种生物标志物进行阿尔茨海默病进展分期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the independent and interactive influences of neuroimaging biomarkers on retrospective cognitive decline. METHODS: A total of 152 middle-aged and older adult participants with at least 2 clinical and cognitive assessments, a Clinical Dementia Rating score of 0 or 0.5, and a flortaucipir (18F-AV-1451) tau PET scan, a florbetapir (18F-AV-45) amyloid PET scan, and a structural MRI scan were recruited from the Knight Alzheimer Disease Research Center at Washington University in St. Louis. Cognition was assessed with standard measures reflecting episodic memory, executive functioning, semantic fluency, and processing speed. RESULTS: Results from retrospective longitudinal analyses showed that each biomarker had a univariate association with the global cognitive composite; however, when each marker was analyzed in a single statistical model, only tau was a significant predictor of global cognitive decline. There was an interaction between tau and amyloid such that tau-related cognitive decline was worse in individuals with high amyloid. There was also an interaction with hippocampal volume indicating that individuals with high levels of all 3 pathologies exhibited the greatest declines in cognition. Additional analyses within each cognitive domain indicated that tau had the largest negative influence on tests of episodic memory and executive functioning. CONCLUSIONS: Together, these results suggest that increasing levels of tau most consistently relate to declines in cognition preceding biomarker collection. These findings support models of Alzheimer disease (AD) staging that suggest that elevated β-amyloid alone may be insufficient to produce cognitive change in individuals at risk for AD and support the use of multiple biomarkers to stage AD progression.
引用
- Aschenbrenner AJ, Gordon BA, Benzinger TLS, et al. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018. PMID: 30068637. doi:10.1212/WNL.0000000000006075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。